ClinicalTrials.gg
Status unknownNCT05395780Updated Jun 2, 2022

A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer

A Phase 2 interventional study of MAX-40279 in Gastric Cancer and Gastroesophageal Junction Cancer, sponsored by Maxinovel Pty., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-06-02.

Sponsored by Maxinovel Pty., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,184 studies in Stomach Neoplasms with a site in China — 481 open to participants now, 557 under way, 50 of them phase 3. Stomach Neoplasms · China.

Planned enrollment
723rd of 881
30 · median 87
Started
2022
with 104 others
Phase 2
323 of 1,184
133 open now
Registered
614th of 1,184
by date

Among the 1,184 studies in Stomach Neoplasms with a site in China, this one is the 723rd largest by planned enrollment of the 881 interventional ones that give a count, is one of 105 that started in 2022, is one of 323 in phase 2, and was the 614th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

481 of the 1,184 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

476 more — sign in →

All 481 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,184 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, multi-center phase II clinical study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With advanced gastric cancer or gastroesophageal junction cancer.

Read the detailed description

This is a single-arm, multi-center phase II clinical study.

This study intends to enroll 20-30 subjects with advanced GC or GEJ adenocarcinoma on second or later lines of treatment (the tumor tissues of ≥ 50% of subjects will be tested by RNAseq, with FGOP2 TPM ≥ 9). Subjects will be randomly assigned to cohort 1 or 2 in a 1:1 ratio:

Cohort 1: High-dose MAX-40279 group (10-15 subjects, 70 mg, BID, PO) Cohort 2: Low-dose MAX-40279 group (10-15 subjects, 50 mg, BID, PO)

03

Conditions studied

  • Gastric Cancer
  • Gastroesophageal Junction Cancer

Browse trials for

Keywords

  • Advanced/ gastric cancer/ gastroesophageal junction cancer.
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation in the clinical study; full understanding of and fully informed of the study and signing of the form (ICF); being willing to follow and able to complete all trial procedures.
  2. Age ≥ 18 years and ≤ 80 years, male or female.
  3. Patients with or cytologically confirmed advanced gastric adenocarcinoma (GC) or gastroesophageal junction (GEJ) adenocarcinoma on the second or later who failed at least the first line of standard treatment.
  4. (ECOG) performance status score of 0-1 point.
  5. Presence of meeting 1.1 criteria.
  6. Expected survival ≥ 12 weeks.
  7. Before administration, patients must provide 5-8 unstained tumor tissue slides (samples taken within 12 months before the first dose) or fresh tissue specimens of ≥ 2 mm3.
  8. Adequate organ and bone marrow functions as defined below (no treatment with blood transfusion, albumin, recombinant human thrombopoietin, or colony-stimulating factor (CSF) within 14 days before the first dose of the drug).
  9. The interval between the first dose of the investigational drug and previous major surgery, treatment with medical devices, or local radiotherapy (excluding palliative radiotherapy) should be at least 28 days; that for previous cytotoxic chemotherapy, endocrinotherapy, or treatment with biologicals should be at least 21 days; that for previous hormonotherapy or minor surgery should be at least 14 days; that for treatment with small-molecule targeted drugs should be at least 14 days or 5 half-lives, whichever is longer;
  10. Female patients of childbearing age must undergo a serum pregnancy test within 7 days before administration of the investigational drug and the results should be negative, and they should be willing to take medically accepted, effective measures (e.g., intrauterine device, contraceptives, or condoms) during the study period and within 3 months after the last dose of the investigational drug; male patients with female partners of childbearing age should have been surgically sterilized, or agree to implement effective contraceptive measures during the study period and within 3 months after the last dose of the investigational drug.

Exclusion criteria

Exclusion Criteria:

  1. Those who were diagnosed of any other within 3 years before the first dose, except for basal cell or squamous cell skin cancer or carcinoma in situ that has been adequately treated.
  2. Known allergy to the drug or any of its .
  3. Those with known Her-2 positive gastric adenocarcinoma or GEJ adenocarcinoma receiving no previous treatment of the target (e.g., Herceptin®) (those with PD can be enrolled after treatment with Herceptin®).
  4. Known and uncontrolled or symptomatic active central nervous system (CNS) manifested as clinical symptoms, cerebral edema, spinal cord compression, carcinomatous meningitis, , and/or progressive growth. History of or spinal cord compression; those who received definite treatment and showed stable clinical manifestations after 4-week discontinuation of anticonvulsants and before the first dose of the investigational drug can be enrolled in the study.
  5. Any previous treatment-induced toxicity that has not been relieved to normal or grade ≤ 1 ( v5.0) before the first dose (except for alopecia, grade ≤ 2 fatigue, poor appetite, and peripheral neurotoxicity).
  6. (HIV) infection or known acquired immunodeficiency syndrome (AIDS), active (HbsAg positive or HbcAb positive and HBV DNA is greater than ), (hepatitis C antibodies are positive, and HCV-RNA is greater than the lower limit of detection for analytical method), or coinfection of hepatitis B and hepatitis C.
  7. Those with serious comorbidities, including but not limited to: uncontrollable active infections, active peptic ulcers, and decompensated respiratory disorders.
  8. Those who have clinical symptoms or signs of gastrointestinal tract obstruction before the first dose and require parenteral fluid replacement or nutrition. Patients with inflammatory bowel diseases or chronic diarrhea. Patients who underwent total gastrectomy.
  9. Presence of following conditions within 6 months before the first dose: myocardial infarction, serious/unstable angina, class > II cardiac insufficiency, poorly controlled arrhythmia (including intervals of > 450 ms for males and > 470 ms for females, by Fridericia's formula), or symptomatic congestive cardiac failure.
  10. Hypertension that cannot be effectively controlled by antihypertensive drugs (systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg).
  11. Known hereditary or acquired hemorrhage and thrombophilia, such as hemophilia, coagulopathy, thrombocytopenia, and hypersplenism.
  12. Presence of significant hemoptysis or daily hemoptysis of up to half a teaspoon (2.5 mL) or more within 2 months before the first dose.
  13. Presence of hemorrhage symptoms (e.g., hemorrhage of digestive tract) or hemorrhagic tendency within 3 months before the first dose, or vasculitis.
  14. Presence of arterial/venous thromboembolic events within 6 months before the first dose, such as cerebrovascular accident (including transient ischemic stroke, cerebral hemorrhage, and cerebral infarction), deep venous thromboembolism, and pulmonary embolism.
  15. Those requiring long-term anticoagulant therapy with warfarin or heparin or long-term antiplatelet therapy (aspirin ≥ 300 mg/d or clopidogrel ≥ 75 mg/d) during the study period.
  16. Pregnant and breastfeeding patients.
  17. Patients with other serious physical or mental diseases or laboratory test abnormalities that may increase the risks for participation in the study or interference with the study results, and patients who are deemed unsuitable to participate in the study as assessed by investigators.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    High-dose MAX-40279 group

    High-dose MAX-40279 capsule group (10-15 subjects, 70 mg, BID, PO)

    Drug: MAX-40279

  • Experimental
    Low-dose MAX-40279 group

    Low-dose MAX-40279 capsule group (10-15 subjects, 50 mg, BID, PO)

    Drug: MAX-40279

Interventions

  • MAX-40279 capsule will be administered orally

    Also known as: MAX-40279-01 capsule

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Progression free survival (PFS)

    Time frame: Through study completion, an average of 1 year

  2. Duration of response (DoR)

    Time frame: Through study completion, an average of 1 year

  3. Disease control rate (DCR)

    Time frame: Through study completion, an average of 1 year

  4. Overall survival (OS)

    Time frame: Through study completion, an average of 1 year

  5. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) and abnormalities in vital signs,electrocardiogram (ECG), and laboratory tests

    Time frame: Through study completion, an average of 1 year

  6. Cmax

    Maximum plasma drug concentration of Max-40279

    Time frame: Through study completion, an average of 1 year

  7. Tmax

    Time to maximum plasma concentration of Max-40279 Time to maximum plasma concentration of Max-40279 Time to maximum plasma concentration of Max-40279 Time to maximum plasma concentration of Max-40279

    Time frame: Through study completion, an average of 1 year

  8. AUC

    Area under the time-concentration curve of Max-40279

    Time frame: Through study completion, an average of 1 year

  9. Correlation between expression level and mutation of FGFR1OP2-related proteins and efficacy

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
  • Nanjing Drum Tower Hospital of Nanjing University Medical School
    Nanjing, Jingsu 210000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2022; primary completion for Dec 2022, 6 months later.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's planned 6 months is below that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2022
First posted
May 27, 2022
StartEst.
Jun 2022
Primary completionEst.
Dec 2022
CompletionEst.
Dec 2023
Last update
Jun 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05395780
Lead sponsor
Maxinovel Pty., Ltd.
Responsible party
Sponsor
First posted
May 27, 2022
Start date
Jun 2022 (estimated)
Primary completion
Dec 2022 (estimated)
Completion
Dec 2023 (estimated)
Last update
Jun 2, 2022

Study contacts

Hanying Bao, MD,Ph.D
Contact
hybao@maxinovel.com
+86-021-51370693

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nefextinib

Start the discussion